The European Myeloma Network reports the required antibodies in the panel as CD38, CD138, CD19, CD45, CD56, CD20, CD117, CD28, and CD27 and recommends that gating, which is of the utmost importance, be carried out according to CD38, CD138, and/or CD45 antibodies. This evidence concerns the gene SDC1 and plasma cell myeloma.